SCHEMBL7147603

SCHEMBL7147603

Cc1ccccc1NS(=O)(=O)CSc1nc2ccccc2s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.57
MAPT P10636 5/20 0.57
ALDH1A1 P00352 3/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
HSD17B10 Q99714 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
CYP1A2 P05177 3/20 0.50
CYP2D6 P10635 3/20 0.50
CYP3A4 P08684 3/20 0.50
CYP2C19 P33261 2/20 0.50
MAPK1 P28482 1/20 0.50
HIF1A Q16665 1/20 0.50
CYP2C9 P11712 2/20 0.48
PTPN1 P18031 1/20 0.48
GAA P10253 1/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.48
APEX1 P27695 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7144783 0.89 LMNA (0.46) LMNAMAPTALDH1A1L3MBTL1HSD17B10
SCHEMBL7146714 0.88 ALDH1A1 (0.62) LMNAMAPTALDH1A1L3MBTL1HSD17B10
SCHEMBL7151670 0.86 LMNA (0.65) LMNAMAPTALDH1A1L3MBTL1HSD17B10
SCHEMBL7148438 0.85 LMNA (0.64) LMNAMAPTALDH1A1L3MBTL1HSD17B10
SCHEMBL7149643 0.85 PDK1 (0.50) LMNAMAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL7154990 0.85 ALDH1A1 (0.49) LMNAMAPTALDH1A1L3MBTL1HSD17B10
SCHEMBL7151678 0.83 MAPT (0.56) LMNAMAPTALDH1A1L3MBTL1HSD17B10
SCHEMBL7154107 0.80 MAPT (0.52) LMNAMAPTALDH1A1L3MBTL1HSD17B10
SCHEMBL7154367 0.78 L3MBTL1 (0.55) LMNAMAPTALDH1A1L3MBTL1HSD17B10
SCHEMBL7144723 0.78 LMNA (0.49) LMNAMAPTALDH1A1L3MBTL1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed
WO-2003043577-A2 MODULATORS OF RHO C ACTIVITY ICONIX PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 LMNA 1481/4885MAPT 3839/4885ALDH1A1 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.